The central nervous system (CNS) is protected by the blood-brain barrier (BBB), a highly selective semipermeable border that prevents solutes in the circulating blood from non-selectively crossing into the extracellular fluid of the brain. While this "fortress" protects the brain from toxins and pathogens, it also serves as the primary obstacle for neurotherapeutics. Systemic administration—swallowing a pill or receiving an IV—often fails because the required dosage to penetrate the BBB would cause toxic levels of exposure in the rest of the body.
To solve this, researchers are developing a suite of localized delivery mechanisms designed to bypass the BBB entirely, delivering "living drugs," genetic material, and nanoparticles directly to the neural tissue.
The Physical Bypass: Direct Intracranial and Intrathecal Delivery
The most intuitive way to bypass a wall is to go through it. In the treatment of aggressive brain tumors like glioblastoma (GBM), researchers like Noriyuki Kijima and Tetsuro Tachi have demonstrated that direct intracranial injection of engineered immune cells (CAR-T and CAR-NK) allows for immediate, high-concentration contact with the tumor site. This method ensures the therapeutic payload isn't diluted by the systemic circulation or blocked by the BBB.
For broader distribution within the CNS, researchers utilize the cerebrospinal fluid (CSF) as a highway. Intrathecal delivery involves injecting agents into the subarachnoid space of the spinal canal. This is particularly effective for:
- Genetic Modulation: Xiaogang Zhou and Pei‑ji Wang used this route to deliver microRNA modulators to treat neuropathic pain.
- Chronic Management: Haruhiko Kishima describes using programmable pumps to deliver baclofen directly to the spinal cord, achieving therapeutic effects with a fraction of the oral dose.
- Complex Disorders: In cases of Spinal Muscular Atrophy, Yi Wang and colleagues showed that intrathecal nusinersen can reach motor neurons effectively even in patients with complex malformations.
Overcoming Diffusion: Convection-Enhanced Delivery
Simple injection relies on diffusion, which is often too slow to move large molecules through the dense "mesh" of the brain's interstitial space. Convection-enhanced delivery (CED) solves this by using a pressure gradient. By maintaining a constant, low-level pressure through an implanted catheter, clinicians can "push" large molecular weight agents—such as the interferons studied by Tanja Eisemann—uniformly across large volumes of brain tissue. This method, highlighted in the ASENT 2006 meeting abstracts, bypasses the BBB to achieve concentrations that are impossible via systemic routes.
The Nasal Backdoor: Olfactory and Trigeminal Pathways
Perhaps the most promising non-invasive strategy is intranasal administration. The upper nasal cavity contains the olfactory mucosa, where sensory nerve endings are directly exposed to the external environment. This creates a unique "neural-mucosal interface."
As Nature Neuroscience documented with SARS-CoV-2, pathogens exploit this route to invade the brain. Researchers are now "hijacking" this same pathway for therapy. By traveling along the olfactory and trigeminal nerves, therapeutic agents can migrate directly from the nasal cavity to the brain, bypassing the BBB and avoiding hepatic first-pass metabolism.
This "backdoor" is being used for a wide range of applications:
- Neuroprotection: Yuanyuan Ma and Guo‐Yuan Yang have explored intranasal delivery for erythropoietin derivatives to treat ischemic stroke and vascular dementia.
- Organelle Therapy: Mengke Zhao and colleagues have even used this route to deliver healthy mitochondria to restore energy in degenerating neurons.
- Nanoparticle Steering: A radical approach proposed in 2018 involves delivering magnetic neuroparticles nasally and using external magnetic gradients to "drill" them into specific deep-brain regions.
Precision Engineering: Nanocarriers and Exosomes
Even with localized routes, the cargo must survive the journey. Researchers are increasingly turning to nanocarriers like liposomes and exosomes (cell-derived vesicles). Zhewei Gu and Zhiyu Yin have shown that exosomes derived from stem cells can cross into diseased tissues safely, providing a "cell-free" alternative to risky whole-cell therapies. Similarly, Xiaolong Tang has developed carbon quantum dots that, when delivered intrathecally, accumulate in the subarachnoid space to scavenge toxins after a brain hemorrhage.
By combining these specialized delivery routes with advanced molecular engineering, the research direction is shifting from "how do we get through the barrier?" to "how do we most effectively go around it?"